资讯

Sarepta Therapeutics获FDA批准恢复Elevidys用于DMD治疗
Elevidys是一种基于腺相关病毒载体的基因疗法，使用Sarepta的AAVrh74平台技术治疗DMD，这是一种由基因缺陷导致的进行性肌肉无力的罕见遗传疾病。该治疗以单次静脉注射的方式给药。
益盟操盘手1 小时
FDA解除对Sarepta安全审查，将立即恢复向治疗中心为行走患者提供药物
7月29日，此前宣布， 美国食品 药品监督管理局已授权该公司恢复向行走患者发送其杜氏肌营养不良症基因疗法ELEVIDYS。受此消息影响，Sarepta Therapeutics 隔夜股价大涨逾16%，盘后续涨逾47%。
Barclays将Sarepta股票评级下调至减持，因Elevidys疗法引发担忧
Investing.com - Barclays周一将Sarepta Therapeutics (NASDAQ: SRPT )的评级从"持平"下调至"减持"，并将目标价从18.00美元大幅下调至10.00美元。该公司股票目前交易价格为11.93美元，年初至今已暴跌90%，接近其52周低点10.41美元。根据 InvestingPro 数据显示，最近有七位分析师下调了其盈利预期。
美国食品药品管理局（FDA）：调查结果显示，八岁男孩的死亡与Sarepta ...
美国食品药品管理局（FDA）：调查结果显示，八岁男孩的死亡与Sarepta Therapeutics的基因疗法Elevidys无关。 返回搜狐，查看更多 ...
基因疗法疑似导致8岁男孩死亡，罗氏出面澄清，FDA介入调查
据外媒报道，美国食品药品监督管理局（FDA）正在调查上个月一名 8 岁男孩的死亡事件，该男孩曾接受过 Sarepta Therapeutics 公司的 Elevidys®（delandistrogene moxeparvovec-rokl）治疗。
Sarepta resumes shipping of gene therapy Elevidys to patients who can walk
Sarepta Therapeutics said on Monday it will resume shipping of its muscular disorder gene therapy to patients who can walk, ...
FDA allows Sarepta to resume some Elevidys shipments
The company can again ship the Duchenne gene therapy for patients who can still walk, following a one-week pause triggered by ...
US FDA recommends removal of hold on Sarepta's Elevidys in some patients
The U.S. Food and Drug Administration said on Monday it is recommending the removal of the hold placed on Sarepta ...
Fierce Pharma4 小时
FDA takes U-turn on Sarepta’s Elevidys, backing Duchenne gene therapy again in ambulatory ...
On Monday, the FDA said Sarepta may resume treating ambulatory Duchenne patients with Elevidys. The recommendation comes just ...
Investing.com South Africa5 小时
Sarepta Therapeutics gets FDA green light to resume Elevidys for DMD
Elevidys is an adeno-associated virus vector-based gene therapy that uses Sarepta’s AAVrh74 Platform Technology to treat DMD, ...
Sarepta Therapeutics Stock Soars After FDA Removes Hold On Elevidys For Some Patients
Sarepta Therapeutics shares are halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) ...
Sarepta Therapeutics to Lift Pause on Shipments of Duchenne Treatment Elevidys
Sarepta Therapeutics said the Food and Drug Administration informed the company it can lift a voluntary pause on shipments of Elevidys for ambulatory patients with Duchenne. The company said Monday ...